Drug
Glesatinib clinical trials
Also written MGCD265.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2009 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Sitravatinib (1) · Mocetinostat (1) · Erlotinib (1) · Docetaxel (1)
Studies
Open first, then newest update. How each study uses glesatinib is read from its arms, and is right about nine times in ten.
Testing it · 6
- Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung CancerTerminatedPhase 2Mirati Therapeutics Inc.NCT02954991Written as Glesatinib
- Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in METCompletedPhase 2Mirati Therapeutics Inc.NCT02544633Written as MGCD265
- Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced MalignanciesCompletedPhase 1Mirati Therapeutics Inc.NCT00697632Written as MGCD265
- Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting StateCompletedPhase 1Mirati Therapeutics Inc.NCT01930006Written as MGCD265
- Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced MalignanciesCompletedPhase 1Mirati Therapeutics Inc.NCT00679133Written as MGCD265
- A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung CancerTerminatedPhase 1Mirati Therapeutics Inc.NCT00975767Written as MGCD265+erlotinib
Codes
What other systems call glesatinib · ClinicalTrials.gg INT000962
- MeSH (NLM) C000627807glesatinibOne source NLM
- UNII (FDA) 7Q29OXD98NGLESATINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27895580glesatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77876GlesatinibOne source FDA
- DrugBank DB06302One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627807 | glesatinib | One source NLM |
| UNII (FDA) | 7Q29OXD98N | GLESATINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27895580 | glesatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77876 | Glesatinib | One source FDA |
| DrugBank | DB06302 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.